Abstract
The purpose of this research was to apply vacuum foam drying (VFD) for processing of LaSota virus and to screen formulation additives for its stability. The aqueous dispersion of harvest containing sucrose or trehalose in combination with additive (monosaccharides, polymers, N-Z-amine) was prepared. The diluted dispersions in vials were vacuum concentrated, foamed to form a continuous structure, and vacuum dried. The products were evaluated for foam characteristics, residual moisture, virus titer, x-ray diffraction pattern, and stability profile. The foamability increased with solid content in solutions. The foamability of sucrose was enhanced with incorporation of N-Z-amine (10% and 15% wt/vol) and polyvinyl pyrrolidone (PVP K30, 3% wt/vol). The fructose- or galactose-containing mixtures were deposited irregularly on the vial surface. The virus titer increased with disaccharides in the formulation. Sucrose provided better protection than trehalose. Unlike lyophilization, N-Z-amine with sucrose protected the virus from Millard’s Browning. Amino acids do not have a catalytic effect on hydrolysis of sucrose during VFD. Monosaccharides were ineffective. A synergistic effect of PVP K30 or polyethylene glycol 6000 (3% wt/vol) with N-Z-amine provided the maximum virus titer (6.97 and 7.15, respectively). This formulation retained the desired virus potency at 5°, 25°, and 40°C. The diffraction pattern revealed that a threshold concentration of N-Z-amine was required for inhibiting crystallization of sucrose during VFD. VFD was successfully applied to produce a solid LaSota formulation. The products were amorphous and did not devitrify on storage.
Keywords: Foam drying, LaSota virus, additives, stabilization
Full Text
The Full Text of this article is available as a PDF (332.1 KB).
References
- 1.Skrabanja AT, Meere AL, Ruiter RA, Oetelaar PJ. Lyophilization of biotechnology products. PDA J Pharm Sci Technol. 1994;48:311–317. [PubMed] [Google Scholar]
- 2.Mumenthaler M, Hsu CC, Pearlman R. Feasibility study on spray dried protein pharmaceuticals: recombinant human growth hormone and tissue type plasminogen activator. Pharm Res. 1994;11:12–20. doi: 10.1023/A:1018929224005. [DOI] [PubMed] [Google Scholar]
- 3.Koseki T, Kitabatake N, Doi E. Freezing denaturation of ovalbumin at acid pH. J Biochem (Tokyo) 1990;107:389–394. doi: 10.1093/oxfordjournals.jbchem.a123055. [DOI] [PubMed] [Google Scholar]
- 4.Pearlman R, Nguyen T. Pharmaceutics of protein drugs. J Pharm Pharmacol. 1992;44:178–185. [PubMed] [Google Scholar]
- 5.Kerwin BA, Heller MC, Levin SH, Randolph TW. Effects of tween 80 and sucrose and acute short-term stability and long-term storage at −20°C of recombinant hemoglobin. J Pharm Sci. 1998;87:1062–1068. doi: 10.1021/js980140v. [DOI] [PubMed] [Google Scholar]
- 6.Mi Y, Wood G, Thoma L, Rashed S. Effects of polyethylene glycol molecular weight and concentration on lactate dehdrogenase activity after freeze-thawing. PDA J Pharm Sci Technol. 2002;56:115–123. [PubMed] [Google Scholar]
- 7.Andersson MM, Hatti-Kaul R. Protein stabilizing effect of polyethyleneimine. J Biotechnol. 1999;72:21–31. doi: 10.1016/S0168-1656(99)00050-4. [DOI] [Google Scholar]
- 8.Ressing ME, Jiskoot W, Talsma H, Van ICW, Beuvery EC, Crommelin DJ. The influence of sucrose, dextran, and hydroxypropylbeta-cyclodextrin as lyoprotectants for a freeze-dried mouse IgG2a monoclonal antibody (MN12) Pharm Res. 1992;9:266–270. doi: 10.1023/A:1018905927544. [DOI] [PubMed] [Google Scholar]
- 9.Nakai Y, Yoshioka S, Aso Y, Kojima S. Solid-state rehydration-induced recovery of bilirubin oxidase activity in lyophilized formulations reduced during freeze-drying. Chem Pharm Bull (Tokyo) 1998;46:1031–1033. [Google Scholar]
- 10.Bronshtein, V, inventor. Scalable long-term shelf preservation of sensitive biological solutions and suspensions. US patent 6 509 146. February 17, 2004.
- 11.Pisal SS, Shah MH, Mahadik KR, Paradkar AR. Process development and lyophilization cycle optimization for lasota vaccine (A57). Fifty Third Indian Pharmaceutical Congress; December 23, 2001; New Delhi, India.
- 12.Kadam SS, Mane JJ, Shah MH, Pisal SS. Effect of excipients on product characteristics and structure of lyophilizedlasota vaccine. Indian J Biotechnol. 2005;4:106–114. [Google Scholar]
- 13.Pisal SS, Wawde GM, More HN, Kadam SS. Vacuum foam drying for preservation oflasota virus: screening of foaming agent and cycle optimization.Indian J Biotechnol. In Press.
- 14.Allan MH, Lancaster JE. Newcastle Disease Vaccines. Rome, Italy: Food and Agricultural Organization of the United Nations; 1978. pp. 52–54. [Google Scholar]
- 15.Wawade GM. Vacuum Foam Drying for Stabilization of Sensitive Biologicals (LasotaVaccine) Pune, India: Bharati Vidyapeeth Deemed University; 2004. [Google Scholar]
- 16.Anchordoquy TJ, Carpenter JF. Polymers protect lactate dehydrogenase during freeze-drying by inhibiting dissociation in the frozen state. Arch Biochem Biophys. 1996;332:231–238. doi: 10.1006/abbi.1996.0337. [DOI] [PubMed] [Google Scholar]
- 17.House JA, Mariner JC. Stabilization of rinderpest vaccine by modification of the lyophilization process. Dev Biol Stand. 1996;87:235–244. [PubMed] [Google Scholar]
- 18.Levine H, Slade L. Another view of trehalose for drying and stabilizing biological materials. Biopharm. 1992;5:36–40. [Google Scholar]
- 19.Nema S, Avis KE. Freeze-thaw studies of model protein, lactate dehydrogenase, in the presence of cryoprotectants. J Parenter Sci Technol. 1993;47:76–83. [PubMed] [Google Scholar]
- 20.Tanaka K, Takeda T. Cryoprotective effect of saccharides on denaturation of catalase by freeze-drying. Chem Pharm Bull (Tokyo) 1991;39:1091–1094. [Google Scholar]
- 21.Arakawa T, Prestrelski SJ, Kenney W, Carpenter JF. Factors affecting short-term and long-term stabilities of proteins. Adv Drug Deliv Rev. 2001;46:307–326. doi: 10.1016/S0169-409X(00)00144-7. [DOI] [PubMed] [Google Scholar]
- 22.Kim AI, Akers MJ, Nail SL. The physical state of mannitol after freeze-drying: effects of mannitol concentration, freezing rate and a noncrystallizing cosolute. J Pharm Sci. 1998;87:931–935. doi: 10.1021/js980001d. [DOI] [PubMed] [Google Scholar]
- 23.Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000;203:1–60. doi: 10.1016/S0378-5173(00)00423-3. [DOI] [PubMed] [Google Scholar]